SINUS-52

DUPIXENT (300 mg Q2W + INCS) reduced polyp burden as early as Week 4, sustained through Week 52 in SINUS-52 as compared to placebo.⁴

There was a reduction in bilateral nasal polyp score as follows:

• Week 4 (SINUS-52): 18% improvement in NPS with DUPIXENT vs 1% worsening with placebo⁴
• Week 24 (SINUS-52): 27% improvement in NPS with DUPIXENT (pooled arms) vs 4% worsening with placebo; LSM difference vs placebo -1.80 (95% CI: -2.10, -1.51) (coprimary endpoint)⁴
• Week 52 (SINUS-52): 39% improvement in NPS with DUPIXENT vs 4% worsening with placebo⁴

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0 to 4 for each nostril, range 0 to 8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.¹

CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See what polyp reduction looks like with DUPIXENT